
PHVS
Healthcare · Biotechnology · $2.36B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | -0.82 | -0.77 | +6.1% |
| Aug 12, 2026 | Before the open | -0.74 | -0.81 | -9.5% |
| Apr 2, 2026 | Before the open | -0.62 | -0.71 | -14.5% |
| Nov 12, 2025 | Before the open | -0.67 | -0.60 | +10.4% |
| Aug 12, 2025 | After the close | -0.77 | -0.83 | -7.8% |
| May 13, 2025 | After the close | -0.83 | -0.85 | -2.4% |
| Nov 13, 2024 | After the close | -0.60 | -0.77 | -28.3% |
| Aug 14, 2024 | Before the open | -0.58 | -0.55 | +5.2% |
| May 8, 2024 | After the close | -0.57 | -0.52 | +8.8% |
| Mar 6, 2024 | Before the open | -0.58 | -0.82 | -41.4% |
| Nov 2, 2023 | Before the open | -0.59 | -0.58 | +1.7% |
| Aug 7, 2023 | Before the open | -0.58 | -0.63 | -8.6% |
| May 8, 2023 | Before the open | -0.76 | -0.67 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema…
| +11.8% |
| Dec 8, 2022 | Before the open | -0.63 | -0.25 | +60.3% |
| Sep 12, 2022 | Before the open | -0.56 | -0.38 | +32.1% |
| May 11, 2022 | Before the open | -0.46 | -0.48 | -4.3% |
| Mar 29, 2022 | Before the open | -0.71 | -0.09 | +87.3% |
| Nov 10, 2021 | Before the open | -0.47 | -0.39 | +17.0% |
| Jul 30, 2021 | Before the open | -0.46 | -0.94 | -104.3% |
| May 26, 2021 | Before the open | -0.35 | -0.66 | -88.6% |
| Feb 9, 2021 | After the close | -1.39 | -2.65 | -90.6% |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.80 | — |